Application of the BAT may help evaluate the propensity for type 1 hypersensitivity and mitigate the perceived risk of administering monoclonal IgE class antibodies directed against tumor-associated antigens as therapeutic agents in cancer patients. This evidence concerns the gene IGHE and neoplasm.